The neurological biomarkers market is entering a transformative phase as healthcare and pharmaceutical research increasingly seek faster, more precise, and less invasive ways to understand neurological disorders. Biomarkers are becoming important not only for diagnosis but also for determining disease progression, evaluating treatment response, supporting patient stratification, and improving neurological drug development. This expanding role is supporting strong market growth, with the global Neurological Biomarkers Market valued at USD 10.2 billion in 2025 and projected to reach USD 27.3 billion by 2033, advancing at a 13.1% CAGR from 2026 to 2033. North America accounted for 41.6% of global revenue in 2025, while Asia Pacific is expected to register the fastest growth.

Key Highlights

The market is shifting from conventional disease assessment toward biomarker-supported neurological care. Alzheimer’s disease accounted for 35.6% of application revenue in 2025, while proteomic biomarkers represented 30.5% of the type segment. Research organizations and others generated the largest end-use share at 43.5%. The market is also benefiting from increasing interest in blood-based biomarkers, precision medicine, highly sensitive assays, neuroimaging, and AI-supported analysis.

Why Neurological Biomarkers Matter More Than Before

Neurological diseases are often complex, progressive, and difficult to characterize using symptoms alone. This is creating demand for biological measurements that can provide information about the underlying disease process.

Download a free sample report or claim your copy of this full market intelligence report

A neurological biomarker can support several stages of care, including:

Early disease detection, Disease classification, Risk assessment, Progression monitoring, Treatment response evaluation, Clinical trial patient selection

The commercial importance of biomarkers is therefore expanding alongside the broader movement toward precision medicine.

Alzheimer’s Disease Leads the Application Landscape

The Alzheimer’s disease segment held a 35.6% revenue share in 2025, making it the largest application within the market.

Alzheimer’s has also become an important testing ground for biomarker innovation.

Research and clinical applications increasingly focus on biomarkers associated with amyloid and tau pathology, along with markers of neuronal injury and neuroinflammation. Cerebrospinal fluid testing and PET imaging have established the value of biomarker-based assessment, while newer blood-based approaches are creating opportunities for broader and more accessible testing.

The growing availability of blood biomarkers is particularly significant because it may allow neurological assessment to become simpler and more scalable across healthcare settings.

Blood-Based Testing Is Changing the Market

For years, neurological biomarker testing faced a major practical challenge: obtaining reliable biological signals from outside the brain.

Advances in highly sensitive analytical technologies are changing that equation.

Platforms capable of detecting extremely low concentrations of proteins in blood are helping expand interest in plasma-based biomarkers such as phosphorylated tau and neurofilament light chain.

This creates a different market proposition:

Less invasive sampling + easier repeat testing + greater accessibility + potential for broader screening

Blood-based testing is therefore becoming one of the most important innovation areas within neurological biomarkers.

Proteomics Holds the Technology Lead

The proteomic segment accounted for 30.5% of market revenue in 2025, supported by growing interest in protein-level changes associated with neurological disorders.

Proteomic analysis can help researchers identify molecular signatures associated with disease development and progression.

Its value extends across:

• Alzheimer’s disease
• Parkinson’s disease
• ALS
• Multiple sclerosis
• Other neurodegenerative disorders

Advances in mass spectrometry, immunoassays, and high-sensitivity protein detection are improving the ability to identify and quantify biomarkers in blood and cerebrospinal fluid.

Parkinson’s Disease Is Creating a New Biomarker Opportunity

While Alzheimer’s currently dominates the application landscape, Parkinson’s disease is becoming another important area for biomarker development.

One of the central challenges in Parkinson’s research is identifying biological changes before neurological symptoms become advanced.

Researchers are therefore investigating biomarkers linked to alpha-synuclein pathology, neuronal injury, protein dysfunction, inflammation, and disease progression.

The opportunity extends beyond diagnosis. Reliable biomarkers could support clinical trials by helping researchers identify appropriate patient populations and evaluate whether investigational therapies are affecting disease-related biology.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs.

Imaging Is Expanding the Definition of a Biomarker

Biomarker development is not limited to laboratory assays.

Advanced neuroimaging is providing another route to disease characterization.

MRI can reveal structural and functional changes.

PET can help visualize specific pathological processes.

Specialized tracers can target disease-associated proteins and other neurological changes.

The combination of imaging and molecular biomarkers can provide a more comprehensive view of neurological disorders, particularly when a single measurement cannot fully capture disease complexity.

AI and machine learning can help analyze relationships among these datasets and identify patterns that may not be obvious through conventional analysis.

This creates an opportunity to move from isolated biomarkers toward integrated neurological profiles.

Research Organizations Remain the Largest End-Use Segment

Research organizations and others accounted for 43.5% of revenue in 2025.

This leadership reflects the importance of biomarkers in drug discovery and clinical research.

As neurological drug development becomes more biomarker-driven, research demand can translate into broader clinical adoption when validated tests move into routine practice.

Technology Is Also Improving Therapeutic Development

The role of neurological biomarkers is becoming increasingly important before a therapy reaches the market. A biomarker can help researchers determine whether a drug is reaching its intended biological target. It can also help identify which patients are most likely to benefit or provide evidence that a treatment is changing disease-related processes.

This can improve the efficiency of clinical development while reducing the uncertainty associated with neurological drug trials.

Regional Growth Is Becoming More Balanced

North America: North America remained the largest regional market with 41.6% revenue share in 2025, supported by advanced healthcare infrastructure, neurological research, clinical trials, regulatory activity, and a strong presence of diagnostic and biotechnology companies.

Asia Pacific: Asia Pacific is expected to record the fastest growth as healthcare infrastructure expands, neurological disease awareness increases, and biomarker research gains momentum. India is projected to reach USD 608.9 million by 2033, growing at a 15.1% CAGR from 2026 to 2033.

Europe: Europe benefits from established biomedical research capabilities, pharmaceutical development, and growing interest in biomarker-guided neurological diagnostics.

Latin America and Middle East & Africa: Improving healthcare systems, expanding diagnostic capabilities, and increasing awareness of neurodegenerative diseases are gradually opening opportunities for biomarker adoption.

The Main Market Challenge

The scientific promise of a biomarker does not automatically translate into clinical adoption.

Before widespread use, biomarkers generally need strong evidence around:

Accuracy

Reproducibility

Clinical validity

Clinical utility

Regulatory acceptance

The cost and complexity of validating neurological biomarkers can therefore slow commercialization. Data privacy, laboratory standardization, and the need for highly specialized expertise can add further challenges.

Key Companies

• Abbott
• Thermo Fisher Scientific, Inc.
• Merck & Co., Inc.
• Bio-Rad Laboratories, Inc.

Explore the full list of profiled companies operating in this market with recent strategic initiatives

The Market Is Moving Toward Integrated Neurology

The next phase of the neurological biomarkers market is likely to be defined by integration rather than by one breakthrough marker.

Blood-based testing can improve accessibility. Proteomics can reveal molecular changes. Imaging can visualize disease-related pathology. AI can connect multiple datasets. Clinical trials can turn those discoveries into therapeutic development tools.

Together, these advances are moving neurological care toward a model in which diseases can be identified earlier, characterized more precisely, monitored more continuously, and treated according to increasingly individualized biological information.

That evolution is expected to remain at the center of the market’s growth as neurological biomarkers move from specialized research applications toward broader roles in clinical diagnostics and precision medicine through 2033.

About us:

Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.